Comparison Of Clinical Effects And Security About Treatment Of Severely Burned Patients With Two Kinds Of Recombinant Human Growth Hormone

Obiective:To explore the clinical effectiveness and safety of recombinant hnman growthhormone(rhGH) on the patients with severe burns.Methods:The study was designed as a randomized single-blind clinical controlled trial.47burned patients were randomly divided into experimental group or control group,23patients in experimental group received Shuanglu rhGH,while the other24patients incontrol group received Haizhiyuan rhGH. Period of treatment was continued for14days. Extract in patients of2groups with venous blood before receiving rhGHtreatment and on the morning of7th,14thday of treatment. Level of insulin-likegrowth factor I (IGF-I), serum protein in2groups was detected on the day of beforetreatment and7th,14thday of treatment. Level of renal function parameters, hepaticfunction parameters, blood routine examination, blood-fasting sugar, healing time ofwound in2groups was observed on the day of before treatment and14thday oftreatment.Results:1. Compared with pre-treatment days, level of IGF-I on7thday of treatmentdecreased, but the level of IGF-I on14thday of treatment had a significant reboundand recovery to the level before treatment in2groups. Two groups the same timepoint was no significant difference on post-treatment days(P＞0.05).2. Compared with pre-treatment days, level of prealbumin and transferrin on7th,14thday of patients in2groups on after treatment days significantly increased(P<0.05or P<0.01). The level of albumin on7thday of treatment decreased, but thelevel of albumin on14thday of treatment had a significant rebound and recovery tothe level before treatment in2groups. Two groups the same time point was nosignificant difference on post-treatment days(P＞0.05).3.The level of white blood count, red blood count and hemoglobin on14thday oftreatment in2groups were significant decreased(P<0.01), while blood platelet was significantly increased (P<0.01) and lymphocyte count was no significant changes.The cell percentage of neutrophile granulocyte was no significant changes inexperimental group, but it was significant decreased(P<0.01) in control group. Therewere no significant difference between2groups on post-treatment days(P＞0.05).4. The level of alanine aminotransferase on14thday of treatment weresignificantly higher than pre-treatment days (P<0.01) in2groups, but the level oftotal bilirubin and creatinine on14thday of treatment were significantly lower thanpre-treatment days in2groups (P<0.05or P<0.01), while blood urea nitrogen, sodiumion, kalium ion and blood-fasting sugar were no significant changes. The differencebetween groups was not significant with P＞0.05.5. Healing time of wound were no significant difference between2groups onpost-treatment days(P＞0.05).Conclusions:1. The experimental rhGH can improve the nutritional status of severity burnedpatients and its clinical effect is the same as similar products.2. The experimental rhGH give little effect on liver and kidney function, bloodroutine examination and blood-fasting glucose in severity burned patients, andadverse reactions was low. So the security equivalent of experimental rhGH is thesame as similar products.